New study finds short oral TB regimens effective and largely safe

Rifampicin-resistant tuberculosis remains a major global health challenge, and the World Health Organization now recommends regimens built around bedaquiline, pretomanid and linezolid. Those combinations — bedaquiline-pretomanid-linezolid (BPaL) and BPaL-moxifloxacin (BPaLM) — were informed by the TB-PRACTECAL trial, but there has been limited clinical data explaining how much of each drug patients actually receive in their blood, how that exposure relates to the killing of Mycobacterium tuberculosis, and how exposure relates to side effects. To fill those gaps, a nested study called PRACTECAL-PKPD was conducted under the leadership of Bern-Thomas B Nyang'wa. The study enrolled people with rifampicin-resistant pulmonary tuberculosis in Belarus and South Africa and set out to measure drug levels and link them to bactericidal activity and toxicity. The trial is registered in ClinicalTrials.gov (TRN: NCT04081077) and was funded by Médecins Sans Frontières. By looking directly at drug exposure and treatment response in people taking investigational short oral regimens, the researchers aimed to provide explanatory clinical data to help interpret the overall TB-PRACTECAL findings.

PRACTECAL-PKPD first developed drug exposure metrics for bedaquiline, pretomanid, linezolid, moxifloxacin and clofazimine, then used those measures to build exposure–response models for each drug and regimen. The team looked at how exposure related to bactericidal activity — measured as the speed of sputum bacterial clearance — and at long-term treatment outcomes, while also testing for exposure–toxicity relationships. Key results reported from the study are clear: overall antimicrobial exposure did not correlate with the speed of sputum bacterial clearance, suggesting that higher blood levels did not produce faster sputum sterilization. Comparing regimens, BPaLM showed a 20% increased bacillary killing rate compared to the standard of care arm, while BPaL and BPaL-clofazimine (BPaLC) showed a 15% decreased bacillary killing rate compared to standard of care. On safety, linezolid plasma exposure was higher among patients who developed anaemia or neutropenia than among those who did not. No other exposure–toxicity relationships were identified for the other drugs.

Taken together, these findings suggest an important interpretation: the dosages used in the studied short oral regimens appear to reach a level where bacillary killing is saturated, meaning that increasing drug exposure beyond those levels does not speed up sputum bacterial clearance. That helps explain why exposure measurements did not predict faster killing and supports the idea that the regimens achieve effective antibacterial activity at the tested doses while remaining largely safe. The specific association between higher linezolid plasma exposure and anaemia or neutropenia highlights a measurable safety signal for that drug, indicating a need to watch blood counts in people taking linezolid. While the study does not report additional exposure-related toxicities for bedaquiline, pretomanid, moxifloxacin or clofazimine, the results provide clinical explanatory data for the TB-PRACTECAL trial outcomes and for WHO-recommended regimens built around these drugs.